The level of antibiotic resistance among hospital and community-acquired isolates has steadily increased and become a major global health problem. Antibiotic resistance pattern of isolates from UTI, which is one of the most frequent infectious diseases and most common infection in hospital and care institution, is also changing (
10). In the present study, which was conducted on
E. coli strains causing urinary tract infections, the most susceptibility was observed to ampicillin, co-trimoxazole, and nalidixic acid. The antibiotic resistance to ampicillin in Jahrom, Hamedan and in similar studies in Turkey, India, Taiwan, and Mexico has been reported as 80.2%, 61.9%, 73.3%, 90%, 82.9%, and 83.7%, respectively (
11-
16). After the ampicillin, co-trimoxazole was the second ranked antibiotic in terms of showing the antibiotic resistance as follows: Jahrom: 76%, Hamedan: 56.4%, and Turkey: 63.3%, which was similar to the present study (
11,
13,
16). In the present study, the most effective antibiotics against
E.coli isolates were amikacin and gentamicin so that only 11% and 20% isolates were resistant to amikacin and gentamicin, respectively. The resistance rate to amikacin and gentamicin was as follows: in Hamadan, 6.1% and 18.8%; in Turkey, 4.9% and 13.9%; and in Mexico, 1.7% and 23.9% (
13,
14,
16).
In the present study, MDR strains were observed in 80% of
E.coli isolates. The level of antibiotic resistance among
E. coli strains causing urinary tract infection varies from country to country. For example, in the United States (2000), India (2012), and Korea (2015), the frequency of MDR strains was reported as 7.1%, 75%, and 21.9%, respectively (
17-
19). In recent years, a high percentage of MDR
E. coli strains have been reported in different parts of Iran (
11,
20-
23). The aim of the present study was to investigate the role of integrons in antibiotic resistance, which plays a broad and important role in MDR
E. coli strains. In the present study, class 1 and 2 integrons of
E.coli isolates were detected in 70% and 3% of isolates, respectively. Previous studies in the other parts of the world also investigated the frequency of different classes of integrons. In a study conducted in 2008 by Farshad
et al., 6.25% and 10.41% of strains had class 1 and class 2 integrons, respectively (
24). In 2011, Rezaee
et al. investigated the prevalence rate of class 1 and 2 integrons among 140 clinical isolates of
E. coli. Their results showed that 22.5% and 5.08% of the isolates had class 1 and class 2 integrons, respectively (
25). In a study conducted in 2013 by Ranjbaran
et al., class 1 and class 2 integrons were detected in 86% and 8% of the isolates, respectively (
26). In a study by Khorramrooz
et al., the frequency of class 1 and 2 integrons was 52% and 2.5%, respectively (
22). In previous studies in California, Pakistan and Syria, the frequency of class 1 integron were reported as 49%, 43.56%, and 54.6%, respectively (
27-
29). In a study in 2015, Lin
et al. showed that 25 isolates of 162 isolates had class 1 integron. No class 2 integron was found in Malaysia (
30).
One of the limitations in the present study was that we were unable to determine gene cassettes carried in the intergrons coding the resistance to the mentioned antibiotics. However, our data indicate that there is a significant correlation between class 1 integrons and resistance to ampicillin, gentamicin, ciprofloxacin, co-trimoxazole, as well as nalidixic acid. The resistance to these antibiotics could be due to the presence of resistance gene cassettes in this class of integrons. In the cases where there was no significant correlation between the presence of class 1 integrons and the antibiotic resistance, the resulting resistance can be achieved through other ways such as the presence of the resistance genes on resistance plasmids and etc. It is recommended to conduct more detailed studies on the nature of integrons, the gene cassettes carried in the intergrons, and the other resistance mechanisms in these species to provide better therapeutics and control strategies in the future.